2023
Di Mambro, A., Arroyo-Berdugo, Y., Fioretti, T., Randles, M., Cozzuto, L., Rajeeve, V., . . . Esposito, M. T. (2023). SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.. Oncogene, 42(50), 3670-3683. doi:10.1038/s41388-023-02840-1DOI: 10.1038/s41388-023-02840-1
2021
Saifullah, H. H., & Lucas, C. M. (2021). Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?. CANCERS, 13(16). doi:10.3390/cancers13164175DOI: 10.3390/cancers13164175
Clark, R. E., Basabrain, A. A., Austin, G. M., Holcroft, A. K., Loaiza, S., Apperley, J. F., . . . Lucas, C. M. (2021). Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. CANCERS, 13(9). doi:10.3390/cancers13092155DOI: 10.3390/cancers13092155
2019
Austin, J. A., Jenkins, R. E., Austin, G. M., Glenn, M. A., Dunn, K., Scott, L., . . . Clark, R. E. (2019). Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells. BIOCHEMICAL JOURNAL, 476, 2255-2269. doi:10.1042/BCJ20190121DOI: 10.1042/BCJ20190121
2018
Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K., & Clark, R. E. (2018). CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances, 2(9), 964-968. doi:10.1182/bloodadvances.2017013615DOI: 10.1182/bloodadvances.2017013615
2016
Lucas, C. M., Milani, M., Butterworth, M., Carmell, N., Scott, L. J., Clark, R. E., . . . Varadarajan, S. (2016). High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X-L in chronic myeloid leukemia. LEUKEMIA, 30(6), 1273-1281. doi:10.1038/leu.2016.42DOI: 10.1038/leu.2016.42
2015
Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients (Journal article)
Lucas, C., Harris, B., Holcroft, A., Scott, L., Carmell, N., McDonald, E., . . . Clark, R. (2015). Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia, 29(7), 1514-1523. doi:10.1038/leu.2015.71DOI: 10.1038/leu.2015.71
C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia (Journal article)
Lucas, C., Harris, B., Giannoudis, A., & Clark, R. (2015). C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica, 100(05), e179-e182. doi:10.3324/haematol.2014.115691DOI: 10.3324/haematol.2014.115691
AKT PHOSPHORYLATION AT SERINE 473 IS A POWERFUL NOVEL BIOMARKER IN ACUTE MYELOID LEUKAEMIA, AND IS RELATED TO PROTEIN PHOSPHATASE 2A (PP2A) INHIBITION BY CIP2A AND SETBP1 (Conference Paper)
Lucas, C., Carmell, N., Scott, L., Holcroft, A., Hills, R., & Clark, R. (2015). AKT PHOSPHORYLATION AT SERINE 473 IS A POWERFUL NOVEL BIOMARKER IN ACUTE MYELOID LEUKAEMIA, AND IS RELATED TO PROTEIN PHOSPHATASE 2A (PP2A) INHIBITION BY CIP2A AND SETBP1. In HAEMATOLOGICA Vol. 100 (pp. 317). doi:10.3324/haematol.2014.115691DOI: 10.3324/haematol.2014.115691
2014
Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia (Journal article)
Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. HAEMATOLOGICA, 99(11), 1710-1715. doi:10.3324/haematol.2013.101972DOI: 10.3324/haematol.2013.101972
Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia (Journal article)
Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia. Haematologica, epub, September 5th 2014.
The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (Journal article)
Giannoudis, A., Davies, A., Harris, B., Lucas, C., Pirmohamed, M., & Clark, R. (2014). The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia, 28(6), 1360-1363. doi:10.1038/leu.2014.38DOI: 10.1038/leu.2014.38
2013
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. (Journal article)
Francis, S., Lucas, C., Lane, S., Wang, L., Watmough, S., Knight, K., . . . Clark, R. E. (2013). A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.. Leukemia research, 37(7), 752-758. doi:10.1016/j.leukres.2013.04.003DOI: 10.1016/j.leukres.2013.04.003
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies (Journal article)
Neelakantan, P., Gerrard, G., Lucas, C., Milojkovic, D., May, P., Wang, L., . . . Marin, D. (2013). Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. BLOOD, 121(14), 2739-2742. doi:10.1182/blood-2012-11-466037DOI: 10.1182/blood-2012-11-466037
Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies (Journal article)
Neelakantan, P., Gerrard, G., Lucas, C. M., Hedgley, C., Milojkovic, D., May, P., . . . Marin, D. (2013). Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies. Blood, 121, 2739-2742.
2012
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. (Journal article)
Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., . . . Foroni, L. (2012). Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(3), 232-238. doi:10.1200/jco.2011.38.6565DOI: 10.1200/jco.2011.38.6565
2011
Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein (Journal article)
Lucas, C. M., Fagan, J. L., Carter, A., Swale, B., Evans, C., Clark, R. E., & Harris, R. J. (2011). Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96(7), 1077-1078. doi:10.3324/haematol.2011.043166DOI: 10.3324/haematol.2011.043166
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (Journal article)
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011). Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. BLOOD, 117(24), 6660-6668. doi:10.1182/blood-2010-08-304477DOI: 10.1182/blood-2010-08-304477
2010
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia (Journal article)
Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 149(3), 458-460. doi:10.1111/j.1365-2141.2009.08066.xDOI: 10.1111/j.1365-2141.2009.08066.x
THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML (Journal article)
Lucas, C., Harris, R. J., Giannoudis, A., & Clark, R. (2010). THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 338. Retrieved from https://www.webofscience.com/
The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia (Journal article)
Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia. British Journal of Haematology, 149, 158-160.
2009
Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript (Journal article)
Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(10), 1362-1367. doi:10.3324/haematol.2009.009134DOI: 10.3324/haematol.2009.009134
Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters (Journal article)
Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., Harris, R. J., . . . Mountford, J. C. (2009). Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. LEUKEMIA, 23(11), 1999-2006. doi:10.1038/leu.2009.166DOI: 10.1038/leu.2009.166
2008
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia (Journal article)
Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. BLOOD, 112(8), 3348-3354. doi:10.1182/blood-2007-10-116236DOI: 10.1182/blood-2007-10-116236
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials (Journal article)
Lucas, C. M., Wang, L., Austin, G. M., Knight, K., Watmough, S. J., Shwe, K. H., . . . Clark, R. E. (2008). A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. LEUKEMIA, 22(10), 1963-1966. doi:10.1038/leu.2008.225DOI: 10.1038/leu.2008.225
2006
The role of serial <i>BCR-ABL</i> transcript monitoring in predicting the emergence of <i>BCR-ABL</i> kinase mutations in imatinib-treated patients with chronic myeloid leukemia (Journal article)
Wang, L. H., Knight, K., Lucas, C., & Clark, R. E. (2006). The role of serial <i>BCR-ABL</i> transcript monitoring in predicting the emergence of <i>BCR-ABL</i> kinase mutations in imatinib-treated patients with chronic myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 91(2), 235-239. Retrieved from https://www.webofscience.com/
